Ovarian Cancer

A significant improvement in progression-free survival was observed in the phase 3 ATHENA-MONO trial with first-line maintenance rucaparib vs placebo in patients with advanced ovarian cancer.

Ira Winer, MD, PhD, FACOG, spoke about which presentations during The Society of Gynecologic Oncology 2022 Annual Meeting he most enjoyed.

A biologics license application for mirvetuximab soravtansine, which demonstrated a clinically meaningful objective response rate, was submitted to the FDA for folate receptor α-high platinum-resistant ovarian cancer that has previously been treated with 1 to 3 lines of systemic treatments.

The phase 3 PRIME study showed increased progression-free survival for patients with newly diagnosed ovarian cancer who were treated with an individualized starting dose of maintenance niraparib vs placebo.

The iPocc trial indicated that patients with ovarian cancer experienced an improvement in progression-free survival when treated with intraperitoneal carboplatin plus paclitaxel compared with intravenous chemotherapy, but this benefit did not translate to overall survival.

Phase 3 SOROYA trial revealed promising response rates with mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer and high folate receptor–alpha expression.

Data presented at 2022 SGO from the phase 2 OVARIO trial show promise of niraparib plus bevacizumab in high-risk ovarian cancer treated with frontline platinum-based chemotherapy.

Patients with pretreated ovarian cancer who are resistant to platinum-based chemotherapy may experience promising responses and disease control following treatment with nemvaleukin alfa and pembrolizumab.

Patients with BRCA-mutant, homologous repair deficiency–positive advanced resectable ovarian cancer may benefit from treatment with neoadjuvant niraparib, according to early results of a phase 2 trial reported at 2022 SGO.

Jhalak Dholakia, MD, discusses the promising neoadjuvant combination of of carboplatin and mirvetuximab soravtansine in folate receptor α–positive advanced-stage ovarian, fallopian tube, or primary peritoneal cancer.

Olaparib and non-platinum chemotherapy produced similar overall survival results when treating patients with platinum-sensitive, relapsed ovarian cancer with BRCA mutations.

No differences in overall and progression-free survival were observed at the GOG-0252 trial update among patients with ovarian cancer who were treated with intravenous or intraperitoneal chemotherapy plus bevacizumab.

Olaparib maintenance therapy will be investigated after receiving first-line chemotherapy for patients with BRCA1/2 wild-type advanced ovarian cancer.

An overview of the phase 3 ARTISTRY-7 trial involving combination therapy with nemvaleukin alfa and pembrolizumab was presented at 2022 SGO.

Long-term progression-free survival was associated with various clinical and molecular factors in patients receiving olaparib who had platinum-sensitive relapsed ovarian cancer and no germline mutations in BRCA1/2.

To assess the oregovomab combination, a phase 3 trial has launched for patients with advanced epithelial ovarian cancer.

The phase 2 CC-ANNIE trial was launched in China investigating anlotinib plus sintilimiab for recurrent platinum-resistant ovarian clear cell carcinoma.

Catherine Watson, MD, discussed the main results and key takeaway from a trial analyzing streamlined and traditional education practices for patients with ovarian cancer.

Patients with recurrent ovarian cancer experienced a longer overall survival and time to next treatment when receiving second-line PARP maintenance compared with active surveillance.

Patients with ovarian clear cell cancer did not seem to derive additional benefit after undergoing retroperitoneal lymphadenectomy.

Adverse effects associated with treatment with olaparib that led to dose reductions and interruptions did not impact survival benefit for patients with platinum-sensitive ovarian cancer.

Fast track designation was granted by the FDA for pidnarulex in patients with BRCA1/2 or PALB2 mutations with ovarian or breast cancer.

A phase 2/3 trial found that patients with low-grade serous ovarian cancer treated with trametinib had improved survival over the standard of care.

Despite universal recommendations for genetic testing, data indicate that the use of germline testing remained underused among women with ovarian cancer who had commercial insurance.

CancerNetwork® spoke with Phillip Low, PhD, about the development and FDA approval of pafolacianine.